Nanotechnology Now - Press Release: ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time

Home > Press > ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time

Abstract:
ThalesNano Inc. and sanofi-aventis R&D today announced the signing of a research and development collaboration agreement focusing on continuous process chemistry technologies.

ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time

BUDAPEST, Hungary, LONDON, UK and PRINCETON, NJ | Posted on May 22nd, 2008

The collaboration will focus on the development and implementation of
continuous process technologies from research to full-scale production. The
purpose of the project is to study the utilization and application of
ThalesNano's integrated continuous process chemistry technologies within the
sanofi-aventis drug R&D process from discovery to API production.

"We are delighted to work with sanofi-aventis R&D who have always been at
the forefront of applying new methods and technologies to improve the drug
discovery and development process," said Dr. Laszlo Urge, CEO of ThalesNano
Inc. "The ThalesNano continuous process technology is already well
established in the discovery labs of the life sciences industry. Taking it to
process scale promises tremendous benefits for our customers in terms of
reducing development time, increasing cost efficiency and minimizing
environmental impact."

Dr. Christophe Daubie, head of Chemical Development for Paris area at
sanofi-aventis R&D said: "this collaboration is important also because it
enters into the scope of sanofi-aventis R&D strategy in terms of our constant
involvement in safety considerations, quality improvement of our processes
with respect to Environmental and Industrial Hygiene aspects, including Green
Chemistry."

Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. "The
benefits of continuous process chemistry over conventional batch chemistry
includes the rapid synthesis of organic compounds, in particular under until
now unrealizable hazardous reaction conditions. Further benefits include
Green Chemistry by minimizing waste, energy consumption and raw material use,
lab automation, and rapid scale-up from mg to kg quantities, which reduces
CAPEX and OPEX while speeding time to market."

####

About ThalesNano Inc.
ThalesNano is a world-leading provider of continuous process chemistry
instruments in the rapidly developing market of laboratory and process scale
flow reactors. The company has the widest portfolio of bench-top continuous
process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow
hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are
used in hundreds of laboratories in four continents and have become the new
industry standard for hydrogenation.

About Sanofi-Aventis:

Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone.

For more information, please click here

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: